Navarra, Spain – January 24, 2025 – Telum Therapeutics, a global biotechnology company specializing in the development of engineered direct acting lytic proteins as novel antimicrobial agents, is proud to announce its membership in the BEAM Alliance. This strategic alliance underscores Telum Therapeutics’ commitment to addressing the escalating challenge of antimicrobial resistance (AMR) through innovative solutions.
Launched in June 2015, the BEAM Alliance (Biotech companies from Europe innovating in Anti-Microbial resistance research) represents over 70 small and medium-sized European companies dedicated to developing innovative products and diagnostics to tackle AMR. The alliance encompasses a diverse range of approaches, including small molecule antibiotics, biologics, microbiome-based and phage-based therapies, immune-targeting treatments, anti-biofilm agents, and medical devices, including in vitro diagnostics. (beam-alliance.eu)
Dr. Subhendu Basu, CEO of Telum Therapeutics, stated, “Joining the BEAM Alliance is a significant milestone in our efforts to combat difficult to treat bacterial infections. We are eager to collaborate with fellow innovators to advance the development of effective solutions against antimicrobial resistance.”
Telum Therapeutics focuses on harnessing engineered phage lytic proteins to develop new treatments for infectious diseases. These engineered proteins offer a promising complementary approach to traditional antibiotics, aiming to overcome the growing issue of bacterial resistance. (telumtherapeutics.com)
By becoming a member of the BEAM Alliance, Telum Therapeutics aims to contribute to and benefit from a collaborative network of European biotech companies, all working towards the common goal of combating AMR.
About Telum Therapeutics
Founded in Navarra in 2019 by Roberto Díez and Rubén Díez, Telum Therapeutics, S.L., is a global drug discovery biotechnology company that develops new treatments for infectious diseases based on the use of lytic enzymes from bacteriophages, called enzybiotics. In 2020, the company raised its first round of financing from Invivo Ventures, with co-investment from Clave Capital and CDTI-Innvierte. (biospace.com)
About BEAM Alliance
The BEAM Alliance represents over 70 small and medium-sized European companies involved in developing innovative products and kits to tackle antimicrobial resistance (AMR). The alliance collaborates with stakeholders to implement tangible strategies and advocates for policies and incentives to stimulate much-needed innovation in antimicrobial research and development in Europe. (beam-alliance.eu)